![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
August 28, 2025
This study is now assessing blood-based and imaging biomarkers to identify patients at elevated risk of pancreatic cysts becoming cancerous
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression
February 10, 2023
Plans for the year ahead; a focus on data; the future of cancer screening studies
February 10, 2023
Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
December 20, 2022
Funding and support are now available to sites to implement natural language processing for recruitment of patients to study EA2185
April 15, 2022
Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
February 24, 2022
Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent